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 In this study, the modulator effect of agmatine on the oxidative 
nephrotoxicity of cyclosporin  (CsA)  in the kidneys of rats was investigated 
by determining indices of lipid peroxidation and the activities of 
antioxidant enzymes, as well as by histological analyses. Furthermore, the 
effect of agmatine on CsA induced hypersensitivity of urinary bladder rings 
to ACh was estimated. Twenty-four male Sprague-Dawley rats were 
randomly divided into three groups, namely control, CsA and CsA plus 
agmatine. At the end of the study, all rats were sacrificed and then blood, 
urine samples and kidneys were taken. CsA administration caused a severe 
nephrotoxicity which was evidenced by an elevation of serum creatinine, 
blood urea nitrogen, serum lactate dehydrogenase and protein in urine 
with a concomitant reduction in serum albumin and creatinine clearance 
as compared with the controls. Moreover, a significant increase in renal 
contents of malondialdehyde, myeloperoxidase and tumor necrosis 
factor-alpha together with a significant decrease in renal reduced 
glutathione, superoxide dismutase activities and nitric oxide content was 
detected upon CsA administration with increasing the sensitivity of 
isolated urinary bladder rings to ACh. Agmatine protected kidney tissue 
against the oxidative damage and the nephrotoxic effect caused by CsA 
treatment.  In addition, agmatine significantly reduced the responses of 
isolated bladder rings to ACh. The results from our study indicate that 
agmatine supplement attenuates CsA -induced renal injury via the 
amelioration of oxidative stress and inflammation of renal tubular cells. 
Exposure to CsA caused vacuolated tubular cells and thickened wall 
vessels, which was found to be prevented by agmatine concurrent 
treatment. Our study indicates that agmatine administration with CsA 
attenuates oxidative-stress associated renal injury by reducing oxygen 
free radicals and lipid peroxidation and inhibiting inflammatory mediators 
such as TNF-α. 
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1. Introduction  
Despite the widespread use of cyclosporin A 
(CsA) as an immunosuppressant in organ 
transplantation and in control of several autoimmune 
diseases (Kovarik and Burtin, 2003), its nephrotoxic 
impact continues to present serious challenges in 
medicine. One key element in the initiation and 
progression of CsA nephrotoxicity is the, imbalance 
between renal vasodilator and vasoconstrictor 
capacities leading to renal ischemia and deterioration of 
renal function (El-Gowelli et al., 2014). Apart from 
primates, the rat appears to be one of the few 
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laboratory species susceptible to cyclosporin-induced 
nephropathy and has been proposed as a model of the 
morphologic and functional changes that occur in the 
human (Moretti et al., 2003). 
The exact mechanism of CsA-induced 
hypertension and nephrotoxicity remain obscure. 
Experimental studies revealed that several mechanisms 
may be involved. These include activation of the renin–
angiotensin system (RAS) (Edwards et al., 1994) and 
increased synthesis of endothelins (Fogo et al., 1992). 
Several studies suggest that a defect in intracellular 
calcium handling (Lo Russo et al., 1996), magnesium 
deficiency (Mervaala et al., 1997), oxidative stress (De 
Nicola et al., 1993), and nitric oxide system (Navarro-
Antolin et al., 1998) are involved. During the last decade, 
considerable attention has been focused on the 
involvement of reactive oxygen species (ROS) in various 
organs including the kidney. ROS have been proposed 
as mediators of different kidney diseases especially in 
toxic, ischemic or immunological conditions (Nath et al., 
2000). The implications of ROS in CsA nephron toxicity 
was strengthened by the fact that many antioxidants 
and free radical scavengers provide marked functional 
and histopathological protection against CsA 
nephrotoxicity (Wongmekiat and Thamprasert, 2005). 
Agmatine, (4-(aminobutyl) guanidine), is formed 
by decarboxylation of L-arginine (Arg) catalyzed by the 
enzyme arginine decarboxylase (ADC). Although 
agmatine and ADC have been recognized in plants, 
bacteria, and invertebrates, for many years they were 
not believed to be synthesized in mammals. Only in 
1994, agmatine and ADC were discovered in the brain of 
rats and bovines (Li et al. 1994) and subsequently in 
many other mammalian organs and cell types (Raasch 
et al., 1995). Studies have shown the various biological 
activities of agmatine that include neuroprotective 
(Hong et al., 2009), cognitive, anxiolytic (Uzbay et al., 
2012), anticonvulsant (Payandemehr et al., 2013), 
antinociceptive (Kotagale et al., 2013), and 
antidepressant properties (Neis et al., 2014).  
Agmatine affects the synthesis of nitric oxide 
(NO) by activating the endothelial NOS (eNOS) while 
inhibiting iducible NOS ( iNOS) (Auguet et al., 1995) and 
neuronal NOS (Demady et al., 2001). Previous studies 
have demonstrated that eNOS-derived NO inhibits 
airway inflammation by suppressing the activation of 
NF-κB, thereby inhibiting both the expression of iNOS 
and the production of inflammatory cytokines (Ten 
Broeke et al., 2006). On the other hand, iNOS derived 
NO may be involved in the infiltration of inflammatory 
cells (Schuiling et al., 1998), mucosal swelling, and 
epithelial damage (Flak and Goldman 1996; Schuiling et 
al., 1998).  
Agmatine can activate α-1 adrenoreceptors and 
imidazolguanidine receptors (Li et al. 1994) and when 
infused into the renal interstitial increases glomerular 
filtration and tubular reabsorption (Schwartz et al. 
1997). Moreover, agmatine administration reduced 
collagen accumulation in kidneys of diabetic mice (Marx 
et al. 1995) as observed with low doses of arginine (Arg) 
administration (Lubec et al. 1997; Radner et al. 1994). 
ADC activity is high in the normal kidney (Morrissey et 
al. 1995) and therefore it is possible that agmatine may 
mediate some of the biological effects of Arg 
supplementation in renal disease. Another interesting 
feature is the ability of agmatine to induce eNOS 
activation and to reduce iNOS synthesis. Agmatine, in 
fact, is metabolized to agmatine aldehyde by diamine 
oxidase. It has been demonstrated that addition of this 
enzyme to cells in culture enhances the effects of 
agmatine as an inhibitor of iNOS, while inhibitors of 
aldehyde dehydrogenase further decrease NO 
generation (Blantz et al. 2000). 
The present study aimed to evaluate the 
potential protective effect of agmatine in an 
experimental model of CsA -induced nephrotoxicity. 
 
2. Materials and Methods 
2.1.  Chemicals 
Agmatine sulfate was purchased as a 
pharmaceutical drug (Agmatine capsule 500 mg) 
obtained from USP labs (Dallas, Texas, USA). CsA was 
purchased as a pharmaceutical drug (Ciclosporin oral 
capsules 50 mg, Sandimmun neoral, Novartis, Egypt). 
All other chemicals and reagents used were of the 
highest analytical grade commercially available. 
 
2.2.  Animals 
Twenty-four adult male Sprague-Dawley rats 
weighing 150-200 g purchased from Vacsera center, 
Helwan, Egypt were used for the experimental 
procedures. Rats were allowed 1 week to adapt to the 
surroundings before beginning any experimentation. 
Animals were housed in individual plastic cages with 
bedding. Standard rat food and tap water were 
available ad libitum for the duration of the experiments 
unless otherwise noted. Temperature was maintained 
at 25 °C with 12/12-h light/dark cycle. All animal 
experiments described in this study comply with the 
ethical principles and guidelines for the care and use of 
laboratory animals adopted by “Research Ethics 
Committee, Faculty of Pharmacy, Mansoura University” 
in agreement with the Principles of Laboratory Animal 
Care (NIH publication no. 85–23, revised 1985). 
 
2.3.  Experimental Design 
The animals were randomly divided into three 
groups containing eight rats in each group. Group (1): 
Control group, rats did not receive any solvent or drug 
during the experiment and were on a usual diet. Group 
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(2): Cyclosporin (CsA) group, CsA was administrated to 
rats (15 mg/kg, S.C.) diluted in olive oil with a ratio 1: 1 for 
four weeks (Lei et al., 2014). Group (3):  Cyclosporin 
/Agmatine (CsA/AG) group, rats were injected with CsA 
(15 mg/kg, S.C.) along with AG (50 mg/kg, orally) 
(Rushaidhi et al., 2012) from the 1st day till the end of 
experimental study.  
 After the last dose, all control and 
experimental animals were immediately kept in 
individual metabolic cages (without prior adaptation) 
for collection of 24 h urine samples. These samples were 
centrifuged for 15 min at 3000 rpm, and kept frozen 
until analyzed. Blood samples were obtained from 
overnight fasted animals through retro-orbital sinus, 
under diethyl ether anesthesia, into non-heparinized 
tubes. The collected blood samples were allowed to 
clot for 30 min. at 25 °C. After clotting, they were 
centrifuged at 1000 x g, 4 °C for 15 min. using cooling 
centrifuge (Damon /IEC Division, Model: CRU-5000, 
Needham, Mass., USA). Sera were collected and stored 
frozen for the determination of levels of Cr, BUN, 
albumin and LDH. The animals were sacrificed after 
anesthesia with diethyl ether by cervical dislocation, 
then the lower abdomen was opened and the 
contractile response of the isolated urinary bladder 
rings towards ACh was tested.  Fatty adherents from 
the kidneys were removed and the kidneys were 
weighed using a digital balance to calculate the kidney 
body weight ratio. The left kidneys were excised 
immediately, rinsed in ice-cold normal saline (0.9% w/v), 
homogenized in 0.1 M phosphate buffer (pH 7.4) to 
yield 10% w/v tissue homogenates that were then used 
for biochemical assays. The right kidneys were 
harvested for histopathological examination. 
 
2.4.  Determination of serum creatinine 
Creatinine was measured in rat sera as described 
by Bartles et al. (1972). Creatinine in alkaline solution 
reacts with picric acid to form a coloured complex that 
was measured spectrophotometrically at 550 nm. The 
amount of the complex formed is directly proportional 
to the creatinine concentration. A kit from 
Biodiagnostic Co., Egypt was used.  
 
2.5.  Determination of blood urea nitrogen (BUN) 
Urea was measured enzymatically in rat sera 
according to (Fawcett and Scott, 1960). Urea in the 
sample was hydrolyzed by urease enzyme to yield 
ammonia and carbon dioxide. In a modified Berthelot 
reaction, the blue dye indophenol product reaction 
absorbs light proportional to initial urea concentration 
and was measured spectrophotometrically at 550 nm. A 
kit from Biodiagnostics Co. was used. 
 
2.6.  Determination of creatinine clearance (Ccr) 
Glomerular filtration was assessed by creatinine 
clearance based on serum and urine creatinine levels, 
with values expressed in ml/min, computed with the 
formula:  
Ccr =urine creatinine (mg/dl) x urine flow 
(ml/min) /Serum creatinine (mg/dl).  
Urine flow was calculated dividing 24 hours of urine 
volume by 1,440, which corresponds to the number of 
minutes in 24 hours (60 min x 24h = 1,440): urine flow 
(ml/min) = value of urine volume (24h)/1,440.  
  
2.7.  Determination of protein in urine: 
Protein in urine was determined by Folin-Lowry 
colorimetric method; two reactions are involved : (a)  an 
initial interaction of protein and   Cu +2 in alkali (related 
to biuret reaction); (b) a reduction of the 
phosphotungstic and phosphomolybdic acids to 
molybdenum blue and tungsten blue both by the Cu-
protein complex and by the tyrosine and tryptophan of 
the protein. The latter two give color in the absence of 
Cu +2 but the rest of the protein gives no color without 
Cu +2. About 75% of the colour is dependent on the Cu+2. 
The maximum absorption of the colored products is at 
750 nm (Daughaday et al., 1952). 
 
2.8.  Determination of serum albumin 
Albumin, in the presence of bromocresol green 
at a slightly acid pH, produces a color change in the 
indicator from yellow-green to green-blue. The intensity 
of the color formed is proportional to the albumin 
concentration in the sample (Doumas et al., 1971). 
 
2.9.  Determination of lactate dehydrogenase 
Lactate dehydrogenase (LDH) activity was 
assessed according to the method described by Henry 
(1974). The method depends on the conversion of 
pyruvate to lactate by LDH consuming NADH+, which 
absorbs at 340 nm. Its consumption is directly 
proportional to serum LDH concentration. LDH activity 
was calculated as units/liter (U/L). 
 
2.10.  Determination of lipid peroxidation 
Lipid peroxidation was determined by the 
method of (Ohkawa et al., 1979). The principle of this 
method being that malondialdehyde (MDA), an end 
product of lipid peroxidation, reacts with thiobarbituric 
acid (TBA) to form a pink chromogen. For this assay, 0.2 
ml of 8.1% w/v sodium dodecyl sulfate (SDS), 1.5 ml of 
20% v/vacetic acid (pH 3.5) and 1.5 ml of 0.8% w/v 
thiobarbituric acid aqueous solution were added in 
succession in a reaction tube. To            this reaction 
mixture, 0.2 ml of the kidney homogenate  
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was added, and the mixture was then heated in boiling 
water for 60 min. After cooling to room temperature, 5 
ml of butanol: pyridine (15:1, v/v) solution was added. 
The mixture was then centrifuged at 2236 x g for 15 min 
following which the upper layer was separated, and the 
intensity of the resulting pink color was read at 532 nm. 
Tetramethoxypropane was used as an external 
standard and the level of lipid peroxides was expressed 
as nmol of MDA formed/g wet tissue. 
 
2.11.  Estimation of superoxide dismutase (SOD) 
activity  
Superoxide dismutase activity in kidney 
homogenates, as an index of endogenous antioxidant 
activity, was measured spectrophotometrically by 
monitoring the SOD-inhabitable autooxidation of 
pyrogallol, as described by Marklund. In brief, the 
reaction mixture consisted of 24 mmol/L of pyrogallol in 
10 mM HCl, Tris buffer (pH 7.8). The reaction was carried 
out at 25◦C. The change in absorbance at 420 nm was 
recorded for 3 min at 1 min interval. One unit of enzyme 
activity is defined as 50 % inhibition of pyrogallol 
autooxidation under the assay conditions. The SOD 
activity was expressed as Unit/ g wet tissue (Marklund, 
1985). 
 
2.12.  Estimation of reduced glutathione (GSH)  
activity Reduced glutathione was determined according 
to the method described by Ellman (1959). The method 
based on the reduction of Ellman’s reagent by (-SH) 
groups of GSH to produce a yellow colored 2-nitro-5-
mercaptobenzoic acid. The produced chromogen is 
directly proportional to GSH concentration. The 
absorbance was measured spectrophotometrically at 
412 nm and the concentrations were expressed as 
µmol/g wet tissue. 
 
2.13.  Measurement of NO2−/NO3− concentration 
Nitrite/nitrate (NO2 −/NO3 −) production, an 
indicator of NO synthesis, was measured in the 
supernatant of the kidney homogenate using a 
commercially available NO assay kit (R&D Systems, 
Minneapolis, USA) following the manufacturer’s 
instruction. 
 
2.14.  Measurement of TNF-α level 
Tumor necrosis factor-alpha concentrations 
were measured in kidney tissue homogenates using an 
enzyme-linked immunosorbent assay kit (R&D Systems 
Inc., USA). Kidney tissue homogenate was added to a 
microtitre plate pre-coated with a monoclonal antibody 
specific for rat tumor necrosis factor-alpha. Incubation, 
plate washing and quenching of reactions were carried 
out according to the kit manufacturer's instruction and 
tumor necrosis factor-alpha levels were expressed as 
pg/mg protein. (Bender Med Systems GmbH, Vienna, 
Austria).  
 
2.15.  Determination of myeloperoxidase (MPO) 
activity  
The neurtophils accumulation in the kidney was 
measured by assaying MPO activity as described by 
Schierwagen et al (1990). Myeloperoxidase activity was 
assayed by measuring the H2O2-dependant oxidation of 
tetramethylbenzidine. Tetramethylbenzidine has a blue 
colour in its oxidized form, which can be monitored 
spectrophotometrically at 450 nm. MPO activity was 
calculated as milliunits/mg wet tissue (mU/mg). 
 
2.16.  Isolation and preparation of urinary bladder 
rings 
Following the collection of blood samples, the 
rats were sacrificed by after anaesethia with diethyl 
ether by cervical dislocation; the lower abdomen was 
opened and the urinary bladder was exposed, the 
connective tissue and accompanying blood vessels 
were cut away, and the bladder was cut into rings and 
placed in a warm physiological salt solution (PSS). The 
composition of the PSS (Mostafa et al., 2003) in g/L was 
as follows: NaCl, 6.9; NaHCO3, 2.1; KCl, 0.35; MgSO4, 
0.15; KH2PO4, 0.16; CaCl2, 0.28; and glucose, 2.0. The 
rings were mounted horizontally between a clamp and 
a force transducer for the measurement of the 
isometric tension in an organ bath that was filled with 
10 mL of the PSS at a temperature of 37 0C and gassed 
with 95 % O2–5 % CO2. The rings were allowed to 
equilibrate for 30 min prior to the experiment under a 
resting load of 1 g (Nakamura et al., 1992). During this 
time, the bath solution was replaced every 5 min. 
Isometric tension generated by the smooth muscle was 
measured by means of an isometric transducer (serial 
no. 88576, Biegestab K30, Hugo Sachs Elektronik, 
Fedral Repuplic of Germany) recorded with a Powerlab 
unit/400 linked to a PC running Chart v 4.2 software 
(ADInstruments Pty Ltd., Australia). Concentration–
response curves to acetylcholine (ACh) were 
constructed. The rings were exposed to different 
concentrations of ACh in a cumulative manner. 
Exposure to each concentration of ACh was maintained 
until the maximal response to that concentration was 
reached. The responses of the bladder rings were 
calculated as g tension/g tissue. 
 
2.17.  Histological examinations 
The kidney tissues of rats were fixed in buffered 
10% neutral buffered formalin solution for 24 h and 
embedded in a paraffin wax. Tissues were then 
sectioned at 5-μm, stained with hematoxylin eosin (H & 
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E). A semiquantitative evaluation of renal tissues was 
accomplished by scoring the degree of severity 
according to the formerly published criteria (Teixeira et 
al., 1982). 
 
2.18.  Statistical analysis 
The values are expressed as mean ± standard 
error of mean (S.E.M), for 8 rats in each group. Bladder 
contraction was calculated as g tension/g tissue. The 
highest response obtained was considered as the 
maximum response (Emax). pEC50 (negative log the 
concentration producing 50 % of maximal response) 
was determined from non-linear regression analysis (4-
parameter curve fit).  Statistical analyses were 
performed using one-way analysis of variance (ANOVA) 
followed by a Tukey–Kramer post-hoc test (Daniel, 
1991). Differences were considered significant at P< 
0.05. Statistical analyses were carried out using Graph 
pad Prism software (GraphPad Software Inc. V4.03, San 
Diego, CA, USA). 
3.  Results 
3.1.  Kidney/Body weight ratio  
The results in figure 1 show that CsA produced a 
significant increase in the kidney body weight ratio 
compared to control rats. In the CsA/AG-treated group, 
the kidney body weight ratio was significantly lower 
than that of the CsA-treated group.  
 
3.2.  Serum biochemical parameters 
3.2.1.  Kidney functions 
CsA caused a significant elevation in serum 
creatinine and BUN and protein in urine compared to 
the control group, with a significant decrease in serum 
albumin and creatinine clearance (CCr). AG 
administration significantly attenuated CsA-induced 
changes in serum creatinine, BUN, CCr and proteinuria 
 
Figure 1. Effect of AG (40 mg/kg) on kidney/body weight ratio in CsA-treated rats. Values are expressed as means ± 
standard error of mean (n = 8). Comparisons performed using one-way ANOVA followed by Tukey-Kramer multiple 
comparisons post hoc test. * p <0.05 vs. control; # p < 0.05 vs. CsA-treated group. 
 
 
Table 1. Effect of AG (40 mg/kg) on kidney function parameters in CsA-treated rats 
 










Control 0.48  ± 0.01 11.1  ± 0.86 0.36  ± 0.01 17.4  ± 0.64 4  ± 0.14 
CsA 4.03  ± 0.1* 84.2  ± 4.5* 0.01  ± 0.0008 * 95.1 ± 3.6* 2.4 ± 0.14* 
CsA/AG 0.56  ± 0.02# 17.8  ± 0.6*# 0.35  ± 0.005# 69.5 ± 1.3# 2.95  ± 0.2* 
 
ANOVA, analysis of variance; CsA, cyclosporin A; AG, Agmatine; SEM, standard error of mean. Data expressed as means ± SEM (n 
= 8). Analyses performed using one-way ANOVA followed by Tukey- Kramer multiple comparisons post hoc test.  
* p < 0.05 vs. control; # p < 0.05 vs. CsA. 
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compared to CsA-treated rats. BUN and serum  albumin 
still significantly different from control group (Table 1). 
3.2.2.  Serum LDH activity 
Figure 2 shows that CsA produced a significant 
increase in LDH activity compared to control rats. In the 
CsA/AG-treated group, LDH activity significantly 




Figure 2. Effect of AG (40 mg/kg) on serum LDH activity 
in CsA-treated rats. Values are expressed as means ± 
standard error of mean (n = 8). Comparisons performed 
using one-way ANOVA followed by Tukey-Kramer 
multiple comparisons post hoc test. * p <0.05 vs. 
control; # p < 0.05 vs. CsA-treated group. 
 
3.2.3.  Antioxidant status  
Table 2 shows that after 4 weeks of treatment, 
CsA significantly increased the MDA levels in rat kidney 
tissue homogenate but decreased both GSH and SOD 
activities. AG significantly decreased the CsA-induced 
changes in MDA levels and significantly increased GSH 
and SOD activities.  
 
Table 2. Effect of AG (40 mg/kg) on kidney anti-oxidant 
status in CsA-treated rats 
 
 MDA (nmol/g) GSH (μmol/g) SOD (U/g) 
Control  7.85  ±  0.5 0.06 ± 0.003 53.1 ± 0.5 
CsA 23.2  ±  1.2* 0.02 ± 0.004* 45.7 ± 0.7* 
CsA/ AG 13.2  ±  1*# 0.06 ± 0.005# 52.8 ± 0.8# 
 
ANOVA, analysis of variance; CsA, cyclosporin; AG, Agmatine; 
SEM, standard error of mean . Data expressed as means ± SEM 
(n = 8). Analyses performed using one-way ANOVA followed 
by Tukey- Kramer multiple comparisons post hoc test.  * p < 
0.05 vs. control; # p < 0.05 vs. CsA 
 
3.2.4.  Renal nitric oxide (NOx) content  
The results in figure 3 show that CsA produced a 
significant decrease in the renal NOx content compared 
to control rats. In CsA/AG-treated group, the renal NOx 
content significantly increased when compared to CsA-
treated group. 
 
Figure 3. Effect of AG (40 mg/kg) on renal NOx content 
in CsA-treated rats. Values are expressed as means ± 
standard error of mean (n = 8. Comparisons performed 
using one-way ANOVA followed by Tukey-Kramer 
multiple comparisons post hoc test. * p <0.05 vs. 
control; # p < 0.05 vs. CsA-treated group 
 
3.2.5.  Tumor Necrosis Factor-α (TNF- α) level in kidney 
tissue homogenate 
Figure 4 shows that CsA produced a significant 
increase in the renal TNF- α level compared to control 
rats. In the CsA/AG-treated group, the renal TNF- α level 




Figure 4. Effect of AG (40 mg/kg) on renal TNF-α level in 
CsA-treated rats. Values are expressed as means ± 
standard error of mean (n = 8). Comparisons performed 
using one-way ANOVA followed by Tukey-Kramer 
multiple comparisons post hoc test. * p <0.05 vs. 
control; # p < 0.05 vs. CsA-treated group. 
 
3.2.6.  Myeloperoxidase (MPO) activity in kidney tissue 
homogenate 
The results in figure 5 show that CsA produced a 
significant increase in the renal MPO activity compared 
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to control rats. In the CsA/AG-treated group, the renal 





Figure 5. Effect of AG (50 mg/kg) on renal MPO activity 
in CsA-treated rats. Values are expressed as means ± 
standard error of mean (n = 8(. Comparisons performed 
using one-way ANOVA followed by Tukey-Kramer 
multiple comparisons post hoc test. * p <0.05 vs. 




Figure 6. Effect of CsA (15 mg/kg) and AG (40 mg/kg) on 
contractions to acetylcholine (ACh) in isolated rat 
urinary bladder rings. Values are expressed as means ± 
standard error of mean (n = 5). Cumulative dose-
response curve to ACh (10−7−10−5 M) was measured. P 
< 0.05 for Emax value compared with control group (*) 
and compared with CsA group (#) using one way 
analysis of variance (ANOVA) followed by Tukey–
Kramer’s multiple comparison post hoc test. 
3.3  Vascular reactivity 
The effects of CsA and AL on the responses of 
bladder rings to ACh are shown in figure 6. The average 
increments in the control urinary bladder rings tension 
after ACh of 0.1, 0.3, 1, 3 and 10 µM were 2 ± 0.3, 5. 2 ± 
0.5, 12.5 ± 0.8, 29.8 ± 0.7 and 63.8 ± 1.9 g tension/g tissue, 
respectively. Treatment with CsA significantly enhanced 
the responsiveness of the rings toward ACh, as 
compared with the control group. Thus, the average 
increments in tension in response to ACh of 0.1, 0.3, 1, 3 
and 10 µM were 17.5 ± 0.79, 53.6 ± 2.5, 137.2 ± 4.1, 250.8 
± 5.2 and 380.9 ± 8.1 g tension/g tissue, respectively. 
Urinary bladder rings, isolated from CsA/AL-treated rats 
showed a significant reduction in their responsiveness 
to ACh when compared to the CsA-treated ones. The 
average increments in their tensions in response to ACh 
of 0.1, 0.3, 1, 3 and 10 µM were 6.2 ± 0.27, 18.8 ± 0.92, 43 





Figure 7. Light micrographs of sections from rat kidneys 
stained with hematoxylin and eosin. (A) control group 
(x100); (B) CsA group (x100); (C) CsA/AG group (X200). 
 
 
3.4. Histopathological results 
The kidney of control rats showed normal 
architecture of glomerulus and tubules (Fig. 7A). Kidney 
of ciclosporin-induced rats showed acute drug toxicity 
with clear vacuolated tubular cells and thickened wall 
vessels in group II (Fig. 7B) animals. Treatment of rats 
with 40 mg/kg/day agmatine along with CsA (group III: 
Fig. 7C), showed no abnormalities in glomeruli, minor 
tubular alteration in form of mild focal tubular injury.                 
4.  Discussion 
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Cyclosporin continues to be the backbone of 
post-transplant immunosuppression. However, side 
effects associated with CsA treatment are numerous 
and kidney dysfunction is the main complication of CsA 
treatment (Chandramohan and Parameswari, 2013).  
The present study demonstrated that CsA 
administration increased the kidney/body weight ratio 
of rats when compared to that of control group. This 
result agreed with our previous study El-Kashef et al. 
(2017).  Administration of AG significantly decreased the 
kidney/body weight ratio of rats when compared to that 
of CsA group. This effect is mediated by its anti-
inflammatory effect. 
In agreement with reported studies (Herlitz and 
Lindelöw, 2000; El-Mas et al., 2003), the present 
findings that CsA caused significant rises in serum 
creatinine and BUN are consistent with impaired renal 
function. However, AG treatment decreased serum 
levels of creatinine, blood urea nitrogen when 
compared to CsA-treared group. This renoprotective 
effect may be due to its action on imidazoline receptor 
(Rouch and Kudo, 2002).  
In the present study, CsA resulted in a significant 
increase in serum level of LDH. This result came in line 
with Ateyya (2015). On the other hand, AG 
administration significantly reduced LDH activity when 
compared to CsA-treated group. AG possesses anti-
inflammatory effect after systemic administration 
(Santos et al., 2005). This anti-inflammatory action 
could account for its lowering effect on serum level of 
LDH. 
CsA intoxication significantly reduced serum 
levels of albumin. This observation agreed with Goksu 
Erol et al. (2012) who detected that CsA caused lower 
serum albumin levels, probably as a result of its side 
effect of albuminuria. Administration of AG with CsA 
failed to retain the level of serum albumin, perhaps 
higher dose was required.  
Proteinuria is an early useful clinical marker to 
detect cyclosporin (CsA) nephrotoxicity (Fernandez-
Fresnedo et al., 2001). In this study, CsA administration 
resulted in increased levels of protein in urine. This 
result is in consistent with Shin et al. (2012) who stated 
that the 24-hour urine protein levels were significantly 
increased in the CsA compared with control group. 
However, AG administration resulted in decreased 
levels of protein in urine when compared to CsA- 
treated group. 
In this study, treatment with CsA significantly 
reduced creatinine clearance when compared to the 
control goup. This result is confirmed by an earlier study 
reported by Chander et al. (2005). AG efficiently 
reversed this CsA induced reduction in creatinine 
clearance. In the current study, CsA caused a significant 
increase in the MDA levels, while GSH and SOD levels 
were significantly decreased in the kidney tissue 
homogenate when compared to control group. This 
result agreed with Ciarcia et al. (2012) who 
demonstrated an increase of MDA content in kidneys 
treated with CsA. In this study, it was shown that 
treatment with CsA significantly reduced SOD and GSH 
activities in kidney, which increased the susceptibility to 
oxidative stress of the cellular structures. Decreased 
SOD and GSH activities are probably due to the reduced 
synthesis or to an increase of the turn-over of such 
enzymes (Deman et al., 2001; Yilmaz et al., 2006). On 
contrast, AG administration significantly decreased 
renal MDA content and significantly increased both GSH 
and SOD activities. This observation is in agreement 
with Khanna et al. (1982).  
The current study showed that CsA 
administration significantly decreased the levels of NOx 
in kidney tissue homogenate. This result agreed with 
Chander et al. (2005) who showed that CsA caused a 
significant decrease in tissue nitrite levels. Previous 
studies have shown that administration of CsA 
stimulates the production of vasoconstriction factors 
such as endothelin, thromboxane A2 and angiotensin II 
(Perico et al., 1986a,b). Studies on endothelial cell 
cultures showed that exposure of cells to CsA results in 
structural damage (Zoja et al., 1996), and several in vitro 
studies reported that acetylcholine-induced 
vasodilation is impaired in vascular beds of CsA-treated 
animals, suggesting a deficient endothelial NO 
synthesis (Diederich et al., 1992; Takenaka et al., 1992), 
although these findings can also be explained by 
enhanced generation of free radicals that inactivates 
NO (Diederich et al., 1994). Mansour et al. (2002) have 
demonstrated that exogenous supplementation of l-
arginine is effective in reducing renal damage induced 
by CsA, possibly through the NO pathway. In addition, 
De Nicola et al. (1993) have shown that oral 
supplementation of l-arginine prevents nephrotoxicity 
induced by chronic supplementation of CsA due to 
formation of more NO which may enhance vasodilation 
and consequently reduce the kidney function 
impairment. Administration of AG elevated the level of 
renal NO when compared to CsA group, but did not 
reach level of significance. 
In this study, CsA-treated rats showed significant 
increase in TNF- α level in kidney tissue homogenate. 
This finding agreed with Abdel-latif et al. (2013) who 
stated that CsA-treated rats exhibited a significant 
increase in the renal expression of TNF-α which may be 
due to renal ischemia and vasoconstriction that are 
commonly associated with CsA administration. Many 
researchers reported that renal ischemia with or 
without reperfusion leads to increase in renal TNF-α 
levels (Donnahoo et al., 2000; Gabr et al., 2011). Further- 
more, the oxidative stress and lipid peroxidation 
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products possibly serve as activators of transcription 
factors, leading to induction of gene expression of pro-
inflammatory cytokines and release of many 
inflammatory cytokines including TNF-α (Mariappan et 
al., 2007). Concerning AG, it significantly decreased  
renal TNF-α level when compared to CsA group. This 
result is consistent with Gu et al. (2011). 
In this study, treatment with CsA increased the 
levels of renal MPO activity. This finding agreed with 
Gökçe et al. (2009) who reported that the activity of 
MPO enzyme and MDA levels in the CsA group were 
significantly increased. Myeloperoxidase is a neutrophil 
and monocyte enzyme that amplifies the reactivity of 
hydrogen peroxide through the generation of 
hypochlorous acid, free radicals, and reactive nitrogen 
species (Heinecke et al., 1993). Myeloperoxidase and its 
oxidative products play a key role for the enzyme in 
promotion of lipid peroxidation, protein nitration, and 
other oxidative modifications (Nicholls and Hazen 
2005). Malondialdehyde is a major lipid peroxidant end 
product, and our present observations are consistent 
with the previous findings indicating the increases of 
lipid peroxidation (Duru et al., 2008; Zal et al., 2007). The 
neutrophil accumulation and the activation of 
myeloperoxidase enzyme is probably indirectly 
responsible for lipid oxidation (Nicholls and Hazen 
2005). Moreover, a correlation has been found between 
neutrophil and MDA levels (Belboul et al., 2000). The 
data obtained suggest that the accumulation of 
neutrophils leads to lipid peroxidation. Administration 
of AG significantly decreased renal MPO activity when 
compared to CsA group. This result agreed with Gu et 
al. (2011), 
In the preseny study, CsA treatment produced 
significant increase in responsiveness of urinary bladder 
rings towards ACh. Afferent arteriole vasoconstriction 
is considered the main mechanism responsible for the 
pathogenesis of CsA-induced acute renal injury 
(Burdmann and Bennett, 2008). This event is mediated 
by the imbalance of vasoactive factors, i.e. an increase 
of vasoconstrictors (such as angiotensin II and 
endothelin) and a decrease in vasodilators (such as 
prostaglandins and nitric oxide) causing 
vasoconstriction (Myers, 1986; English et al., 1987; 
Burdmann and Bennett, 2008). On the other hand, AG 
administration retained normal response of urinary 
bladder rings towards ACh. The histological studies of 
kidney from CsA treated rats showed clear vacuolated 
tubular cells and thickened wall vessels. However, AG 
attenuated that change.  
In summary, we have confirmed that AG has a 
protective role against nephrotoxicity induced by CsA 
exposure. According to our biochemical findings, which 
were supported by histopathological and sensitivity of 
urinary bladder rings to ACh, administration of AG 
rescued the cells from the effects of CsA. These findings 
indicate that AG administration might reduce CsA-
induced renal injury. Therefore, we propose that AG 
might be a potential candidate agent against CsA 
induced nephrotoxicity via its antioxidant and anti-
inflammatory properties. 
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